Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?
Author:
Affiliation:
1. Department of Medicine, Massachusetts General Hospital Cancer Center, and Harvard Medical School, Boston
2. West Cancer Center and Research Institute, OneOncology, Germantown, Tennessee
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2765324/jamaoncology_corcoran_2020_ed_200002.pdf
Reference8 articles.
1. PD-1 blockade in tumors with mismatch-repair deficiency.;Le;N Engl J Med,2015
2. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers.;Salem;Mol Cancer Res,2018
3. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types.;Wang;JAMA Oncol,2019
4. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.;Eng;Lancet Oncol,2019
5. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt mCRC: findings from cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction chemotherapy.;Grothey;Ann Oncol,2018
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity;Nature Communications;2024-09-03
2. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers;Nature;2024-04-24
3. Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer;Cancer Medicine;2023-12-19
4. Clinical prospects of WRN inhibition as a treatment for MSI tumours;NPJ PRECIS ONCOL;2022
5. Clinical prospects of WRN inhibition as a treatment for MSI tumours;npj Precision Oncology;2022-11-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3